Patient-Reported Outcomes Following the Use of Jiang Tang San Huang Tablets in Type 2 Diabetes Mellitus: A Retrospective Cohort Study in a Chinese Population

Cui Shao; Mengxue Sun; Wanwen Liu; Shaoyang Zhao; Yang Liu; Yuna Chen; Shu-Nung Liang; Haoyu Yuan; Huacheng Sui; Baohua Wang; Saimei Li

doi:10.2147/DMSO.S388336

Patient-Reported Outcomes Following the Use of Jiang Tang San Huang Tablets in Type 2 Diabetes Mellitus: A Retrospective Cohort Study in a Chinese Population

Diabetes Metab Syndr Obes. 2022 Dec 23:15:4023-4033. doi: 10.2147/DMSO.S388336. eCollection 2022.

Authors

Cui Shao^#¹, Mengxue Sun^#², Wanwen Liu², Shaoyang Zhao¹, Yang Liu², Yuna Chen¹, Shu-Nung Liang², Haoyu Yuan², Huacheng Sui², Baohua Wang¹, Saimei Li¹

Affiliations

¹ Department of Endocrinology, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
² First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.

^# Contributed equally.

Abstract

Purpose: We aimed to assess the efficacy of the Jiang Tang San Huang (JTSH) tablet for the treatment of patients with type 2 diabetes mellitus (T2DM).

Methods: All data for this retrospective cohort study were acquired from the outpatient clinic database of our institution, and all enrolled patients received JTSH tablet for at least two months. Overall, 147 patients were included in the analysis. The primary outcome was patient-reported outcomes on the efficacy of the JTSH tablets using a questionnaire survey. Correlation analysis evaluated the duration of JTSH tablet administration and glycemic control in patients with T2DM. The secondary outcome measures included: changes in glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), 2-hour postprandial blood glucose, homeostasis model assessment of insulin resistance index (HOMA-IR) and homeostasis model assessment of β-cell function (HOMA-β) after 2 months of treatment with JTSH tablets.

Results: Overall,120 patients (81.63%) reported a JTSH tablet treatment satisfaction score of ≥60 points, and believed that JTSH tablets had satisfactory hypoglycemic effects and could improve symptoms. The average duration of JTSH tablet treatment was 2.57±1.45 years. Overall, 111 patients achieved good blood glucose control, while 36 patients had poor glycemic control. Multivariate logistic regression model analysis showed that taking JTSH tablets for 1 year might reduce the risk of poor hypoglycemic effect by 17.00% (Risk ratio=0.830, 95% confidence interval:0.578, 1.021, P=0.066). Compared with the baseline data, the levels of HbA1c, FPG and HOMA-IR decreased significantly and HOMA-β levels increased significantly (P<0.05).

Conclusion: Good blood glucose control may be positively correlated with the duration of JTSH tablets administration. Patients with T2DM were satisfied with the anti-diabetic effects of JTSH tablets, which can significantly reduce blood glucose and insulin resistance, and improve the function of islet cells.

Keywords: Jiang Tang San Huang tablet; blood glucose control; multiple logistic regression; patient-reported outcomes; type 2 diabetes mellitus.

Grants and funding

This work was supported by the Fundamental and Applied Research Fund of Guangdong Province. (No. 2021A1515220066).